[go: up one dir, main page]

WO2005123721A3 - Amorphous and polymorphic forms of candesartan cilexetil - Google Patents

Amorphous and polymorphic forms of candesartan cilexetil Download PDF

Info

Publication number
WO2005123721A3
WO2005123721A3 PCT/IB2005/001739 IB2005001739W WO2005123721A3 WO 2005123721 A3 WO2005123721 A3 WO 2005123721A3 IB 2005001739 W IB2005001739 W IB 2005001739W WO 2005123721 A3 WO2005123721 A3 WO 2005123721A3
Authority
WO
WIPO (PCT)
Prior art keywords
candesartan cilexetil
polymorphic forms
amorphous
present
novel polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/001739
Other languages
French (fr)
Other versions
WO2005123721A2 (en
Inventor
Yatendra Kumar
Shantanu De
Swargam Sathyanarayana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2005123721A2 publication Critical patent/WO2005123721A2/en
Publication of WO2005123721A3 publication Critical patent/WO2005123721A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides a storage-stable, substantially pure amorphous form of candesartan cilexetil. The present invention further provides novel polymorphic forms of candesartan cilexetil, process for preparation and pharmaceutical compositions thereof for antagonizing angiotensin II. The novel polymorphic forms have been designated as Form A and Form B of candesartan cilexetil.
PCT/IB2005/001739 2004-06-18 2005-06-20 Amorphous and polymorphic forms of candesartan cilexetil Ceased WO2005123721A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1154DE2004 2004-06-18
IN1154/DEL/2004 2004-06-18
IN1312DE2004 2004-07-16
IN1312/DEL/2004 2004-07-16

Publications (2)

Publication Number Publication Date
WO2005123721A2 WO2005123721A2 (en) 2005-12-29
WO2005123721A3 true WO2005123721A3 (en) 2006-06-08

Family

ID=35094269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001739 Ceased WO2005123721A2 (en) 2004-06-18 2005-06-20 Amorphous and polymorphic forms of candesartan cilexetil

Country Status (1)

Country Link
WO (1) WO2005123721A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2008035360A2 (en) * 2006-06-13 2008-03-27 Alembic Limited Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
KR20090049089A (en) * 2006-09-05 2009-05-15 아스트라제네카 아베 Pharmaceutical composition comprising candesartan cilexetil
ES2315141B1 (en) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A PROCEDURE FOR THE PREPARATION OF CARDESARTAN CILEXETILO IN CRYSTAL FORM.
EP1952806A1 (en) 2007-02-01 2008-08-06 Helm AG Process for the preparation of adsorbates of candesartan
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009057A1 (en) * 2002-07-18 2004-01-29 Astrazeneca Ab Process for the preparation of crystalline nano-particle dispersions
WO2004085426A1 (en) * 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009057A1 (en) * 2002-07-18 2004-01-29 Astrazeneca Ab Process for the preparation of crystalline nano-particle dispersions
WO2004085426A1 (en) * 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIROKAZU MATSUNAGA ET AL: "Solid-state characterization of candesartan cilexetil (TCV-116): crystal structure and molecular mobility", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 47, no. 2, February 1999 (1999-02-01), pages 182 - 186, XP002957606, ISSN: 0009-2363 *

Also Published As

Publication number Publication date
WO2005123721A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2007052289A3 (en) Novel dispersible tablet composition
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2006023627A8 (en) Rapamycin polymorph ii and uses thereof
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
WO2007090882A3 (en) Pharmaceutical extended release compositions comprising pramipexole
EP2460797A3 (en) Process for preparation of ivabradine hydrochloride
WO2009025876A3 (en) Crystalline forms of erlotinib hcl and formulations thereof
WO2008057291A3 (en) Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
WO2006074951A3 (en) Orally disintegrating composition of olanzapine or donepezil
WO2003059807A3 (en) Crystalline solids of carvedilol and processes for their preparation
WO2007001065A3 (en) Method for the preparation of a wet granulated drug product
WO2006128150A3 (en) Crystalline solid forms of tigecycline and methods of preparing same
WO2006035277A3 (en) Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2005084648A8 (en) Pharmaceutical compositions comprising candesartan cilexetil
WO2008035360A3 (en) Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
WO2005123721A3 (en) Amorphous and polymorphic forms of candesartan cilexetil
IL183104A0 (en) Method for production of candesartan
WO2005077941A3 (en) Candesartan cilexetil polymorphs
WO2008129077A3 (en) Crystalline 1-(cyclohexyloxycarbonyloxy) ethyl 1-((2'-cyanobiphenyl-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate and a process for its preparation
WO2009021943A3 (en) Novel preparation process
WO2008075163A3 (en) An improved process for the preparation of rizatriptan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase